Science


Through patent-centric innovation, Novo Nordisk brings advanced treatments to people living with haemophilia and rare bleeding disorders. With a broad portfolio of innovative products and a focused clinical pipeline, we engage with the scientific community to share knowledge and thus improve haemophilia care.

Science is part of our commitment to changing haemophilia.

 

Novo Nordisk haemophilia research

At Novo Nordisk we are committed to changing haemophilia through pioneering research - working towards the next breakthrough.

Through patent-centric innovation, Novo Nordisk brings advanced treatments to people living with haemophilia and rare bleeding disorders. With a broad portfolio of innovative products and a focused clinical pipeline, we engage with the scientific community to share knowledge and thus improve haemophilia care.

Science is part of our commitment to changing haemophilia.

 

Novo Nordisk haemophilia research

At Novo Nordisk we are committed to changing haemophilia through pioneering research - working towards the next breakthrough.

Building on our experience in protein and peptide design, Novo Nordisk has continued to discover and develop effective and safe medicines for people with haemophilia and other rare bleeding disorders. 

Through patent-centric innovation, Novo Nordisk brings advanced treatments to people living with haemophilia and rare bleeding disorders. With a broad portfolio of innovative products and a focused clinical pipeline, we engage with the scientific community to share knowledge and thus improve haemophilia care.

Science is part of our commitment to changing haemophilia.

 

Novo Nordisk haemophilia research

At Novo Nordisk we are committed to changing haemophilia through pioneering research - working towards the next breakthrough.

Building on our experience in protein and peptide design, Novo Nordisk has continued to discover and develop effective and safe medicines for people with haemophilia and other rare bleeding disorders. 

Building on our experience in protein and peptide design, Novo Nordisk has continued to discover and develop effective and safe medicines for people with haemophilia and other rare bleeding disorders. 

Lisbeth Delorang Andersen, Global Research, Novo Nordisk

 

Our successful research programmes mean that, today, we offer innovative products and have a rich pipeline of next-generation longer-acting and efficacious medicines capable of delivering effective prophylaxis and reducing the treatment burden for patients.

 

Infographic


Show your commitment to haemophilia and share the infographic.

Download infographic (PDF)

 

Facts and figures